Jean‐Pierre Delord

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

Carola H. Ries, Michael A. Cannarile, Sabine Hoves et al. · Cancer Cell · 2014 · 1.4K citations

Medicine, Immunology, Oncology +16

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder et al. · JAMA Oncology · 2018 · 793 citations · Full text

Medicine, Oncology, Pharmacology +17